Orasure Technologies, Inc. · NASDAQ:OSUR
Orasure Technologies — Investor Presentation (September 2020)
23 slides from Orasure Technologies's investor presentation, Sep 1, 2020
Slide 1: OraSure Technologies Investor Presentation September 2020
OraSure Technologies Investor presentation september 2020 Exhibit 99.1
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause act
Slide 3: Company Snapshot
Company Snapshot 1 Excludes net revenue of cryosurgical business, which was divested in August 2019 2 Cash and cash equivalents, short-term investments, and long-term investments as of June 30, 2020 Note: Other revenue consists of royalty income and funded research and development, grants, and reimb
Slide 4: Investment Rationale
Investment Rationale Multiple Near-term COVID-19 Opportunities and Long-term Growth Drivers Market leading microbiome products and services offer tremendous growth potential Continued expansion in global markets with OraQuick HIV Self-Test and OraQuick HCV test Investment in manufacturing capacity a
Slide 5: Improving Global Access to Accurate Healthcare Information
Improving Global Access to Accurate Healthcare Information Experts in sample collection, preservation and diagnostics Over 20 years of proprietary knowledge in oral fluid testing enables self collection and rapid in-home results Broad, well-established channels of distribution across global public h
Slide 6: Capitalizing on Next-generation Health and Wellness Technologies
Capitalizing on Next-generation Health and Wellness Technologies Innovative sampling tools, services and diagnostics help people understand what’s in us, on us, and around us Unlocking access to accurate essential information that advances global health and well-being Driving access to multiple laye
Slide 7: OraSure Solutions
OraSure Solutions Best-in-class tools and chemistries Multiple samples/analytes Study design Customization Single-order fulfillment Wet lab & sequencing Analysis Consulting Infectious disease Substance abuse testing Sampling Sample collection & stabilization devices to drive discovery and access Ser
Slide 8: Innovation and Expertise in Infectious Disease Diagnostics
Innovation and Expertise in Infectious Disease Diagnostics Our technologies are the ideal platform for the emerging trends in diagnostic testing Directly suited for the current COVID-19 testing dynamic Leveraging our proven experience with HIV Self-Test and Rapid Ebola Antigen Test to develop a Coro
Slide 9: Three Distinct COVID-19 Opportunities: Current Progress
Three Distinct COVID-19 Opportunities: Current Progress+ OraQuick Coronavirus Rapid Antigen Self-test Would use a nasal sample easily collected from the lower nostril to maximize accuracy and convenience Currently in clinical testing with human subjects Expected launch in Q4 2020 following EUA Initi
Slide 10: OraQuick Coronavirus Rapid Antigen Self-Test
Game-changing test to detect active COVID-19 infection anytime, anywhere with direct results a short time later No instrumentation or trained personnel required to administer the test or to read results Enables testing scale BARDA contract to develop a coronavirus rapid antigen self-test Based on ou
Slide 11: OraQuick Coronavirus Rapid Antigen Self-Test: Three Parallel Pathways to Launch
OraQuick Coronavirus Rapid Antigen Self-Test: Three Parallel Pathways to Launch Phased approach to EUA to bring product to market as quickly as possible Clinical Trial Pathway Rapid antigen self-test is currently in human clinical testing This will provide the necessary, real-use data to file for FD
Slide 12: SARS-CoV-2 Oral Fluid Antibody Test
To-date, there are no other oral fluid COVID-19 antibody tests Easy and non-invasive self-collection ELISA Microplate lab-based oral fluid test Short turn-around time and high-throughput Ideal for surveillance data BARDA contract to develop Aiming for initial product sales and EUA in Q420 Sars-Cov-2
Slide 13: COVID-19 Molecular Sample Collection Devices
All-in-one, easy, reliable and non-invasive self-collection High quality DNA and RNA Ambient temperature stability Compatible with high throughput processing Four customers to date* have received EUAs incorporating our sample collection products with more expected to follow All-in-one solutions for
Slide 14: Expansion of Manufacturing Capacity to Meet Anticipated Demand
Expansion of Manufacturing Capacity to Meet Anticipated Demand for COVID-19 Opportunities Current capacity for 35 million OraQuick test per year including HIV, HCV and Ebola tests+ Installation of new lines will expand total capacity for all tests to 55 million tests per year Further expansion will
Slide 15: Trailblazer in HIV Self-Testing
Trailblazer in HIV Self-Testing First and only rapid HIV in-home test approved by FDA First and only WHO-prequalified rapid oral HIV self-test Source: WHO/UNITAID/UNAIDS 21% of the 38 million people with HIV do not know their status Safe, accurate, convenient point-of-care and in-home HIV tests key
Slide 16: Well-Positioned to Play an Important Role in the Eradication of HIV in the U.S.
Well-Positioned to Play an Important Role in the Eradication of HIV in the U.S. ENDING THE HIV EPIDEMIC: THE PLAN FOR AMERICA The Plan for America continues with $267 million in FY 2020 funding and meaningful increase proposed for FY 2021 Reaching the difficult to reach is key to achieving plan goal
Slide 17: Hepatitis C
Hepatitis C Source: WHO & CDC * VWB and FSWB only 81% of the estimated 71 million people with chronic Hepatitis C do not know their status Antiviral medications can now cure 95%+ of those infected but access to diagnosis and treatment is low Opioid crisis is fueling the Hepatitis C epidemic OraSure
Slide 18: Opportunities in Substance Abuse Testing
Opportunities in Substance Abuse Testing New federal guidelines permit oral fluid drug testing SAMHSA estimates oral fluid testing will grow from 7% today to 25% of total testing by 2025 OraSure pioneered oral fluid testing for substance abuse Socially distanced, easier, less costly and more efficie
Slide 19: DNA Genotek: The Magic Behind Human Genomics
DNA Genotek: The Magic Behind Human Genomics DNA Genotek “has done for DNA collection what Google did for Web searches: made it ridiculously simple and efficient.” – TIME Magazine Pioneer in DNA/RNA sample collection, stabilization and preparation products Technology stabilizes DNA for long periods
Slide 20: Microbiome Impact on Healthcare
Microbiome Impact on Healthcare The microbiome is believed to influence many diseases and biological processes Gastrointestinal diseases, Type 1&2 Diabetes, skin conditions, the urinary tract, women’s health and neonatal health It provides a means of intercepting disease and personalizing treatments
Slide 21: Services: Unmatched Offering From Sample to Answer
Services: Unmatched Offering From Sample to Answer Blue-chip customer base and technical innovation in microbiome analysis and DNA Genotek’s microbiome sampling kits Integrating lab operations in Minnesota Consolidated CoreBiome and Diversigen services under Diversigen brand Diversigen represents ex
Slide 22: Multiomics: New Health Paradigm
Multiomics: New Health Paradigm End-to-end quality in sampling, services, and bioinformatics Multifactorial examination of an individual’s health Informing health, wellness, infectious disease, chronic disease and cancer Introduced first and only commercially available device for in-home, self-colle
Slide 23: Business Development
Business Development 1 Cash and cash equivalents, short-term investments, and long-term investments as of June 30, 2020 Using robust balance sheet to create revenue and shareholder value Considering infectious disease possibilities as well as molecular $266 million in cash on balance sheet1 with no
OraSure Technologies — Investor Presentation (September 2020) on 6ix